Published May 12, 2023 | Version v1
Journal article Open

2 días frente a 5 días de levofloxacino en la agudización de EPOC

Creators

  • 1. Medicina Interna. Hospital Universitario General de Villalbava

Description

La duración del tratamiento antibiótico en la agudización de enfermedad pulmonar obstructiva crónica (EPOC) generalmente está basada en opinión de expertos. Habitualmente se mantiene entre 5 y 7 días. El tratamiento corto de 2 días con levofloxacino no ha sido estudiado previamente. En este ensayo aleatorizado se valora su eficacia.

 

 

Duration of antibiotic treatment in chronic obstructive pulmonary disease (COPD) exacerbation is generally based on expert opinion, usually maintaining it between 5-7 days. Short 2-day treatment with levofloxacin has not been previously studied. Its efficacy is assessed in this randomized trial.

Files

Journal 60 - 5.pdf

Files (1.3 MB)

Name Size Download all
md5:2a1abbfc1964cc07dae20b40f6c83567
1.3 MB Preview Download

Additional details

References

  • Vol 104 N10; pág. 1396-1403. 2010. Anzueto A., Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respiratory Medicine. DOI: https://doi.org/10.1016/j.rmed.2010.05.018
  • Vol 94 N1; pág. 18-27. 2000. Chodosh S., DeAbate C.A., Haverstock D., et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respiratory medicine. DOI: https://doi.org/10.1053/rmed.1999.0708
  • Vol 44 N4; pág. 515-523. 1999 Langan C.E., Zuck P., Vogel F. et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrob Chemotherapy. DOI: https://doi.org/10.1093/jac/44.4.515
  • Vol 72. 2022. Llor C., Moragas A., Miravitlles M. et al. Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. Pulmonary Pharmacology & Therapeutics. DOI:https://doi.org/10.1016/j.pupt.2022.102111
  • Vol 25 N6; pág 1001- 1010 Martinez F.J., Grossman R.F., Zadeikis N. et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25(6):1001-1010. DOI: https://doi.org/10.1183/09031936.05.00106404